<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03965208</url>
  </required_header>
  <id_info>
    <org_study_id>1665-2019</org_study_id>
    <nct_id>NCT03965208</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation</brief_title>
  <acronym>BIV-ECMO2</acronym>
  <official_title>Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation: an Open Label, Parallel Group Randomized Pilot Study (BIV-ECMO2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Legacy Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pacific University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Legacy Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate heparin as compared to bivalirudin for systemic anticoagulation in
      adult patients that require extracorporeal membrane oxygenation (ECMO). Half of the
      participants will receive heparin and half will receive bivalirudin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will randomly assign 34 adult patients requiring ECMO to receive
      bivalirudin or unfractionated heparin in a 1:1 fashion. There will be 17 patients in each
      group for a total of 34 patients.

      Unfractionated heparin binds to antithrombin thereby causing an anticoagulant effect while
      bivalirudin binds directly to thrombin. Use of unfractionated heparin in this population is
      problematic due to reliance on adequate levels of circulating antithrombin, complex
      pharmacokinetics, and variable clearance. Bivalirudin avoids many of these difficulties.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of time in the target anticoagulation range</measure>
    <time_frame>From ECMO cannulation (start of ECMO) until patient is decannulated up to 12 weeks</time_frame>
    <description>activated partial thromboplastin time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major bleeding events</measure>
    <time_frame>From ECMO cannulation (start of ECMO) until patient is decannulated up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major clinical thrombotic events</measure>
    <time_frame>From ECMO cannulation (start of ECMO) until patient is decannulated up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of oxygenator use</measure>
    <time_frame>From ECMO cannulation (start of ECMO) until patient is decannulated up to 12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of blood products received</measure>
    <time_frame>From ECMO cannulation (start of ECMO) until patient is decannulated up to 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of patients that reach the target anticoagulation range within the first 24 hours</measure>
    <time_frame>From ECMO cannulation (start of ECMO) until patient is decannulated up to 12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Extracorporeal Membrane Oxygenation Complication</condition>
  <condition>Anticoagulants</condition>
  <arm_group>
    <arm_group_label>Unfractionated heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to this group will receive anticoagulation with unfractionated heparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bivalirudin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this group will receive anticoagulation with bivalirudin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bivalirudin</intervention_name>
    <description>titrated continuous infusion</description>
    <arm_group_label>Bivalirudin</arm_group_label>
    <other_name>Angiomax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Unfractionated heparin</intervention_name>
    <description>titrated continuous infusion</description>
    <arm_group_label>Unfractionated heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years

          2. Require ECMO and systemic anticoagulation as determined by the primary treating
             physician

          3. Require anticoagulation to target an activated partial thromboplastin time (aPTT) of
             40-60 seconds or 60-80 seconds

        Exclusion Criteria:

          1. Prior inclusion in this study

          2. Patients with known or suspected heparin induced thrombocytopenia

          3. Systemic anticoagulation at Legacy for ≥ 24 hours during ECMO immediately prior to
             study enrollment

          4. Allergy to heparin or related products or bivalirudin

          5. Known anti-thrombin deficiency

          6. Selection of a non-standard aPTT target range
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R Brigg Turner, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pacific University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>R Brigg Turner, PharmD</last_name>
    <phone>503-352-7288</phone>
    <email>brigg.turner@pacificu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joseph Deng, MD</last_name>
    <phone>503-413-2000</phone>
    <email>jdeng@lhs.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Legacy Health System</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Deng, MD</last_name>
      <phone>503-413-2000</phone>
      <email>jdeng@lhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Kyle Kojiro, PharmD</last_name>
      <phone>503-413-2000</phone>
      <email>kkojiro@lhs.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2019</study_first_posted>
  <last_update_submitted>May 24, 2019</last_update_submitted>
  <last_update_submitted_qc>May 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Legacy Health System</investigator_affiliation>
    <investigator_full_name>R. Brigg Turner</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Bivalirudin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

